A significant milestone achieved, Actinogen has enrolled final patient into XanADu. A total of 186 patients have been enrolled into XanADu, surpassing initial target of 174.
View recent announcement
Find out more on XanADu, Xanamem and cortisol in Alzheimer’s and other neurological diseases. View video with commentary from Dr Bill Ketelbey and the Xanamem Clinical Advisory Board
Dr Bill Ketelbey, CEO, provided a business overview of Actinogen Medical presenting 2018 Highlights and 2019 Outlook at the recent AGM on 28 Nov 2018.
|30.11.2018||Appendix 3B-Exercise of Options|
|28.11.2018||Appendix 3Z-Dr Jason Loveridge|
|28.11.2018||Retirement of Dr Jason Loveridge as a Non-Executive Director|
|28.11.2018||Results of Annual General Meeting (AGM)|
|28.11.2018||Managing Director’s AGM Presentation|
|28.11.2018||Chairman’s AGM Address|
|26.11.2018||Final patient enrolled in landmark Alzheimer’s trial-XanADu|
LINK MARKET SERVICES
Level 12, 680 George Street
Sydney NSW 2000
Locked Bag A14
Sydney South NSW 1235
+61 1300 554 474
Level 1, 28 Ord Street
West Perth WA 6005
NATIONAL AUSTRALIA BANK
1232 Hay Street
West Perth WA 6005
ERNST & YOUNG
11 Mounts Bay Road
Perth WA 6000
Video: XanADu, Xanamem & Cortisol: Oct 2018 Barcelona
Actinogen has achieved a major milestone through enrolling the final patient into XanADu, its landmark trial in Alzheimer’s disease. Find out more on XanADu, and Xanamem and cortisol in Alzheimer’s and other neurological diseases, with commentary from Dr Bill Ketelbey and the Xanamem Clinical Advisory Board.
Questions can be submitted via email to firstname.lastname@example.org
The Company listed on the Australian Securities Exchange in 2007 as Actinogen Limited. In 2014, the Company acquired Corticrine, a company focused on the development of treatment for Alzheimer’s disease. The drug in development by Corticrine was Xanamem. Corticrine received $25m support from the Seeding Drug Discovery program of the Wellcome Trust and the University of Edinburgh and successfully completed a Phase 1 single ascending dose (SAD) study of UE2343 in healthy human volunteers. Corticrine then became part of Actinogen Limited and the company subsequently rebranded to become Actinogen Medical in 2015.
Suite 901, Level 9, 109 Pitt Street, Sydney, NSW 2000
The share registry is managed by Link Market Services. To login and access your holding information, please go to: https://www.linkmarketservices.com.au
The share registry is managed by Link Market Services and shareholders can check their shareholdings by logging into https://www.linkmarketservices.com.au
All company shares are traded on the ASX and can be bought or sold through a licensed stock broker. The process of buying or selling shares is explained on the ASX website, please go to https://www.asx.com.au/products/shares/buying-selling-shares.htm
Non-Australian residents wishing to invest in ACW shares should contact a licensed stock broker which offers cross border transaction services with Australia. Alternatively, online trading platforms offer solutions for overseas investors to invest in international equities. Investors should note that ACW is only listed on the Australian Securities Exchange.
All annual reports are available on our website through this link – https://actinogen.com.au/acw-investor-centre/#newsletter-and-reports
The ASX ticker code for the Company is ASX:ACW
The latest financial reports can be found on our website at https://actinogen.com.au/acw-investor-centre/#newsletter-and-reports
Key reporting dates are as follows:
The Company’s end of financial year is the 30th of June
As a listed company Actinogen is required to hold its annual general meeting within five months of its financial year end. Accordingly, shareholders will be notified in the months of September or October, approximately 28 days in advance of when and where the AGM will be held. Typically, Actinogen holds its AGM towards the end of November.
The Company’s auditors are Ernst and Young
Our Corporate Governance policy can be found on our website at: https://actinogen.com.au/acw-investor-centre/#corporate-governance . This includes our Board Charter, Code of Conduct, Continuous Disclosure Policy, Directors Skills Matrix, Diversity Policy, Nomination Committee Charter, Performance Evaluation Practices, Procedures for Selection and Appointment of Directors, Remuneration Committee Charter, Risk Management and Internal Compliance and Control, the Securities Trading Policy and Shareholders Communication Policy.
The Company does not currently have a dividend policy as the Company is not yet revenue generating. The Board reviews its growth strategy at regular intervals and assesses its against the Company’s working capital requirements and growth opportunities. Until the Company is generating returns, it is not expected to implement a dividend policy.